Every 10-Q that Rockwell Medical, Inc. (DE) (RMTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RMTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMTI filings page.
Rockwell Medical, Inc. reported modest top-line growth and narrower losses for the quarter and six months ended June 30, 2026. Second-quarter net sales were $17.8 million, up 11% from a year earlier, driven mainly by $1.3 million of sales to new customers in the Western U.S. and price increases to existing accounts. Gross profit rose to $3.2 million with margin improving to 18% from 16%, helped by lower manufacturing headcount and overhead.
For the first half of 2026, net sales were $35.1 million, essentially flat year over year, as growth from new and existing customers offset a $4.3 million decline in sales to DaVita and the absence of $0.3 million of prior-year license revenue. Net loss for the six months narrowed to $2.8 million from $3.0 million, and operating cash flow turned positive at $1.9 million versus a $1.6 million outflow. The company ended the quarter with $24.8 million in cash, cash equivalents and available-for-sale investments, working capital of $25.2 million, and term loans of $9.0 million outstanding under an interest-only structure through early 2027. A 1-for-10 reverse stock split became effective July 1, 2026 to regain Nasdaq minimum bid compliance; all share data are presented on a split-adjusted basis. Management states it believes current resources are sufficient to fund operations for at least 12 months while it continues cost containment and pursues additional growth and potential capital-raising options, including $13.1 million remaining under its at-the-market equity program.
Rockwell Medical, Inc. reported first-quarter 2026 results showing slightly lower sales but stable losses and improved cash use. Net sales were $17.3 million, down 8% from $18.9 million a year earlier, mainly from reduced DaVita purchases, partly offset by higher pricing and new customers.
Gross profit was $2.9 million with a 17% margin, similar to last year, and net loss was $1.6 million, or $0.04 per share. DaVita accounted for 7% of sales versus 27% in 2025, reducing customer concentration. Operating cash outflow improved sharply to about $0.2 million from $3.5 million.
Rockwell ended March 31, 2026 with $23.9 million in cash, cash equivalents and available-for-sale investments and working capital of $27.1 million. Management states these resources, plus $13.1 million remaining under its at-the-market equity program, are expected to fund operations for at least 12 months.
Rockwell Medical (RMTI) reported a weaker quarter. Q3 2025 net sales were $15.9 million versus $28.3 million a year ago, driving gross profit of $2.3 million and an operating loss of $1.6 million. Net loss was $1.8 million, or $0.05 per share, compared with net income of $1.7 million last year.
For the first nine months, net sales were $50.9 million versus $76.8 million, with a net loss of $4.8 million. Cash, cash equivalents and available-for-sale investments totaled $23.7 million, and net working capital was $27.9 million; management believes funds are sufficient for at least the next twelve months.
DaVita extended its purchase agreement through December 31, 2025 but is transitioning to another supplier. Rockwell recognized non-refundable payments of $1.7 million year-to-date, including $0.4 million in Q3, and continues to supply DaVita. The company raised $8.0 million gross ($7.8 million net) via its ATM in Q3, with $13.1 million remaining available. Rockwell closed its Greer, South Carolina facility, recording $0.5 million in Q3 and $0.8 million year-to-date in closure costs. Term loan balance was $8.7 million, interest-only through 36 months, with all covenants in compliance. Shares outstanding were 39,405,301 as of September 30, 2025.
Rockwell Medical (RMTI) reported a sharp decline in sales following reduced volumes from its largest customer. Net sales were $16.1 million for the quarter (down 38% year-over-year) and $35.0 million for the six months (down 28%). Gross margin held near 16%, but the company recorded a net loss of $1.5 million for the quarter and $3.0 million year-to-date, driven largely by a $9.9 million quarterly reduction in DaVita purchases and a $14.6 million reduction for the six-month period.
Liquidity sources include $18.4 million of cash, cash equivalents and short-term investments, $21.1 million available under an ATM facility, and net working capital of $20.7 million; management believes these resources are sufficient for at least the next twelve months. The Company has an outstanding term loan with a net carrying amount of $8.6 million, current deferred consideration of $2.5 million, and completed remediation with its lender by submitting updated projections. The Company also disclosed a new multimillion-dollar supply agreement with IRC with three-year utilization commitments.